ReviewJournal of current ophthalmology
The Use of Topical Tacrolimus as Adjunct Therapy to Corticosteroid in a High-Risk Penetrating Keratoplasty: A Systematic Review and Meta-Analysis.
Review in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the use of topical tacrolimus as an adjunct therapy to corticosteroids in preventing graft rejection in high-risk penetrating keratoplasty (PKP). Methods: A comprehensive search was conducted through PubMed Results: Five studies comprising 298 eyes were included in the study. Rejection rates were found significantly lower in the tacrolimus group (RR: 0.63; 95% confidence interval [CI]: 0.46-0.88; Conclusions: Tacrolimus successfully reduces the rejection rate and irreversible rejection in high-risk PKP patients. Improved visual acuity was observed. There were no significant side effects; however, further studies are still needed to achieve more quantitative results, like recommended concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.